Eravacycline - SOM Biotech
Latest Information Update: 28 Nov 2024
At a glance
- Originator SOM Biotech
- Developer Ewha Womans University; SOM Biotech
- Class Acetamides; Anti-infectives; Antibacterials; Antivirals; Fluorinated hydrocarbons; Pyrrolidines; Small molecules; Tetracyclines; Urinary anti-infective agents
- Mechanism of Action Coronavirus 3C-like proteinase inhibitors; Peptide hydrolase inhibitors; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in South Korea (IV)
- 28 Nov 2024 No recent reports of development identified for preclinical development in COVID-2019-infections in Spain (IV)
- 12 Nov 2020 Chemical structure information added